肿瘤标记物联合检测对肺癌诊断的价值  

THE CLINICAL SIGNIFICANCE OF TUMOR MARKERS COMBINATION MEASUREMENT IN DIAGNOSIS OF LUNG CANCER

作　　者：余秉翔[1] 胡斌[2] 陈良安[1] 

机构地区：[1]解放军总医院 [2]安徽铜陵市人民医院

出　　处：《解放军医学杂志》2003年第4期354-355,共2页Medical Journal of Chinese People's Liberation Army

摘　　要：探讨联合检测癌胚抗原 (CEA)、神经元特异性烯醇化酶 (NSE)、细胞角蛋白片段 (CYFRA2 1 1)在肺癌诊断中的应用价值。应用放射免疫法分别检测 75例肺癌患者和 2 2例肺良性疾病患者血清中CEA、NSE、CYFRA2 1 1水平。结果显示 ,CEA在肺腺癌中的水平最高 ,NSE在肺小细胞癌中的水平最高 ,CYFRA2 1 1在肺鳞癌中的水平最高。CEA +NSE +CYFRA2 1 1联合检测肺癌的阳性率为 82 .6 7%。提示CEA、NSE、CYFRA2 1To study the clinical significance of combined measurement of neuron specific enolase(NSE), carcinoembryonic antigen(CEA) and Cytokeratin19 fragment 21 1 (CYFRA 21 1 ) in the diagnosis of lung cancer. The serum levels of CEA, NSE, and CYFRA 21 1 in 75 lung cancer patients as well as in 22 benign pulmonary diseases patients were measured by radioimmunoassay. Patients with pulmonary adenocarcinoma had a highest CEA level. Small cell lung carcinoma (SCLC) patients had a highest NSE level, while patients with squamous cell carcinoma of lung had a highest CYFRA 21 1 level. The positive rate of the combination of CEA, NSE, and CYFRA 21 1 for lung cancers was 82 67%. The results suggested that the combined measurement of CEA, NSE, and CYFRA 21 1 was helpful in the diagnosis of lung cancer.

关 键 词：肿瘤标记物 联合 检测 肺癌 诊断 

分 类 号：R734.204[医药卫生—肿瘤]